J&J faces a pivotal talc verdict. Jim Cramer looks at the stock

Johnson & Johnson (JNJ) could be at a turning point in its years-long talc legal battles.

Related Keywords

California ,United States ,America ,Jim Cramer ,Emory Hernandez ,Michael Kaplan ,Johnson ,Club Monthly Meeting On ,Jj Jim Cramer Charitable ,Anthony ,Monthly Meeting ,Charitable Trust ,Biotech And Pharmaceuticals ,Corteva Inc ,Dupont De Nemours Inc ,Chemours Co ,3m Co ,Johnson Amp ,Breaking News Markets ,Markets ,Investment Strategy ,Stock Takes ,Business News ,